Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (611-620 of 636) with videos related to

Pageof 64
Sort By:
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Hepatology (Baltimore, Md.)|October 18, 2024
Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver diseaseMonica A Tincopa, Luis Antonio Díaz, Daniel Q Huang, et al.
Nature Medicine|August 7, 2024
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseasesJanani S Iyer, Dinkar Juyal, Quang Le, et al.
Hepatology (Baltimore, Md.)|March 11, 2026
Original research: Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiencyChristina Schrader, Malin Fromme, Paul Ellis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 8, 2025
Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated SteatohepatitisArun J Sanyal, Atsushi Nakajima, Elisabetta Bugianesi, et al.
Nature Medicine|November 4, 2024
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitisHanna Pulaski, Stephen A Harrison, Shraddha S Mehta, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2025
Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Kaleb Tesfai, Luis Antonio Díaz, Juan Pablo Arab, et al.
Gut|July 25, 2023
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysisElina En Li Cho, Chong Zhe Ang, Jingxuan Quek, et al.
Science Translational Medicine|December 15, 2021
A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaquesXiao-Jing Zhang, Yan-Xiao Ji, Xu Cheng, et al.
Hepatology Communications|February 5, 2024
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statementHannes Hagström, Leon A Adams, Alina M Allen, et al.
Pageof 64

Showing results (611-620 of 636) with videos related to

Sort By:
Pageof 64
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Hepatology (Baltimore, Md.)|October 18, 2024
Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver diseaseMonica A Tincopa, Luis Antonio Díaz, Daniel Q Huang, et al.
Nature Medicine|August 7, 2024
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseasesJanani S Iyer, Dinkar Juyal, Quang Le, et al.
Hepatology (Baltimore, Md.)|March 11, 2026
Original research: Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiencyChristina Schrader, Malin Fromme, Paul Ellis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 8, 2025
Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated SteatohepatitisArun J Sanyal, Atsushi Nakajima, Elisabetta Bugianesi, et al.
Nature Medicine|November 4, 2024
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitisHanna Pulaski, Stephen A Harrison, Shraddha S Mehta, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2025
Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Kaleb Tesfai, Luis Antonio Díaz, Juan Pablo Arab, et al.
Gut|July 25, 2023
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysisElina En Li Cho, Chong Zhe Ang, Jingxuan Quek, et al.
Science Translational Medicine|December 15, 2021
A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaquesXiao-Jing Zhang, Yan-Xiao Ji, Xu Cheng, et al.
Hepatology Communications|February 5, 2024
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statementHannes Hagström, Leon A Adams, Alina M Allen, et al.
Pageof 64